使用免疫组织化学技术检测头颈部鳞状细胞癌中的 PD-L1 表达。
Determining PD-L1 expression in head and neck squamous cell carcinoma using immunohistochemistry.
机构信息
Department of Pathology, Command Hospital, Pune, Maharashtra, India.
Department of Otorhinolaryngology, Command Hospital, Pune, Maharashtra, India.
出版信息
Indian J Cancer. 2022 Oct-Dec;59(4):474-479. doi: 10.4103/ijc.IJC_920_19.
BACKGROUND
Advanced head and neck squamous cell carcinoma (HNSCC) has limited treatment options. Programmed death-ligand1 (PD-L1) expressed by tumor cells interacts with PD-1 receptor on T lymphocytes leading to immune evasive response and survival advantage. Therapy with immune check-point inhibitors target PD-1/PD-L1 blockade inducing tumor regression. Immunohistochemistry (IHC) for PD-L1 expression enables patient selection for immunotherapy and may be considered a potential predictor of clinical response.
METHODS
A retrospective analysis of IHC for PD-L1 expression using manual laboratory developed technique (LDT) with antibody clone 22C3 (Dako) in 93 cases of HNSCC. PD-L1 expression was correlated with age, gender, tumor site, grade and stage.
RESULTS
PD-L1 IHC was performed in 93 cases and immunopositivity was noted in 59 (63.4%) cases. High expression with combined proportion score (CPS) ≥50 was seen in 15 (16.1%) cases and low expression with CPS ≥1 expression was seen in 44 (47.3%) cases. An almost-perfect interobserver agreement was noted by two pathologists for PD-L1 IHC expression (Cohen's kappa coefficient = 0.910). No statistically significant correlation was noted between PD-L1 score and patient demographics, tumor site, grade or stage.
CONCLUSION
Detection of PD-L1 status by IHC enables identification of HNSCC patients eligible for future targeted immunotherapy.
背景
晚期头颈部鳞状细胞癌（HNSCC）的治疗选择有限。肿瘤细胞表达的程序性死亡配体 1（PD-L1）与 T 淋巴细胞上的 PD-1 受体相互作用，导致免疫逃避反应和生存优势。免疫检查点抑制剂的治疗靶向 PD-1/PD-L1 阻断，诱导肿瘤消退。PD-L1 表达的免疫组织化学（IHC）使患者能够选择免疫治疗，并且可以被认为是临床反应的潜在预测因子。
方法
对 93 例 HNSCC 患者使用 Dako 公司的 22C3（克隆）抗体进行手动实验室开发技术（LDT）的 PD-L1 表达的回顾性分析。PD-L1 表达与年龄、性别、肿瘤部位、分级和分期相关。
结果
对 93 例进行了 PD-L1 IHC 检测，59 例（63.4%）呈免疫阳性。15 例（16.1%）为高表达（联合比例评分（CPS）≥50），44 例（47.3%）为低表达（CPS≥1）。两位病理学家对 PD-L1 IHC 表达的观察结果几乎具有完美的一致性（Cohen's kappa 系数=0.910）。PD-L1 评分与患者的人口统计学特征、肿瘤部位、分级或分期之间无统计学显著相关性。
结论
通过 IHC 检测 PD-L1 状态可确定适合未来靶向免疫治疗的 HNSCC 患者。
Zotero 插件